SCOPUS 정보 검색 플랫폼

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 301-303

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma

(3) Lindholm, Daniel P a Eriksson, Barbro a Granberg, Dan a

a UPPSALA UNIVERSITY HOSPITAL (Sweden)

Author keywords

Case report; Chemotherapy; PDEC; Poorly differentiated neuroendocrine carcinoma; Temozolomide

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; ETOPOSIDE; OCTREOTIDE; TEMOZOLOMIDE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CANCER GROWTH; CASE REPORT; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE TUMOR; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; THORAX PAIN; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; DACARBAZINE; FEMALE; HUMANS; LIVER NEOPLASMS; SALVAGE THERAPY;

EID: 84864053729 PISSN: 13570560 EISSN: 1559131X Source Type: Journal
DOI: 10.1007/s12032-010-9789-4 Document Type: Article

Times cited : (13)

References (10)

1
- 20044372154
- MGMT gene silencing and benefit from temozolomide in glioblastoma
- DOI 10.1056/NEJMoa043331
- Hegi ME, et al. MGMT gene silencing and benefit from tem-ozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003. (Pubitemid 40349502)
- (2005) New England Journal of Medicine , vol.352 , Issue.10 , pp. 997-1003
- Hegi, M.E.¹ Diserens, A.-C.² Gorlia, T.³ Hamou, M.-F.⁴ De Tribolet, N.⁵ Weller, M.⁶ Kros, J.M.⁷ Hainfellner, J.A.⁸ Mason, W.⁹ Mariani, L.¹⁰ Bromberg, J.E.C.¹¹ Hau, P.¹² Mirimanoff, R.O.¹³ Cairncross, J.G.¹⁴ Janzer, R.C.¹⁵ Stupp, R.¹⁶

2
- 0033989205
- Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
- Middleton MR, et al. Randomized phase III study of temozolo-mide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18(1):158-66. (Pubitemid 30036349)
- (2000) Journal of Clinical Oncology , vol.18 , Issue.1 , pp. 158-166
- Middleton, M.R.¹ Grob, J.J.² Aaronson, N.³ Fierlbeck, G.⁴ Tilgen, W.⁵ Seiter, S.⁶ Gore, M.⁷ Aamdal, S.⁸ Cebon, J.⁹ Coates, A.¹⁰ Dreno, B.¹¹ Henz, M.¹² Schadendorf, D.¹³ Kapp, A.¹⁴ Weiss, J.¹⁵ Fraass, U.¹⁶ Statkevich, P.¹⁷ Muller, M.¹⁸ Thatcher, N.¹⁹

3
- 34249818466
- Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
- DOI 10.1158/1078-0432.CCR-06-2053
- Ekeblad S, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13(10):2986-91. (Pubitemid 46849574)
- (2007) Clinical Cancer Research , vol.13 , Issue.10 , pp. 2986-2991
- Ekeblad, S.¹ Sundin, A.² Janson, E.T.³ Welin, S.⁴ Granberg, D.⁵ Kindmark, H.⁶ Dunder, K.⁷ Kozlovacki, G.⁸ Orlefors, H.⁹ Sigurd, M.¹⁰ Oberg, K.¹¹ Eriksson, B.¹² Skogseid, B.¹³

4
- 58849093671
- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
- Kulke MH, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009; 15(1):338-45.
- (2009) Clin Cancer Res , vol.15 , Issue.1 , pp. 338-345
- Kulke, M.H.¹

5
- 0027197245
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- DOI 10.1038/362841a0
- Kim KJ, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-4. (Pubitemid 23132159)
- (1993) Nature , vol.362 , Issue.6423 , pp. 841-844
- Kim, K.J.¹ Li, B.² Winer, J.³ Armanini, M.⁴ Gillett, N.⁵ Phillips, H.S.⁶ Ferrara, N.⁷

6
- 0030856731
- Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
- Presta LG, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-9. (Pubitemid 27441066)
- (1997) Cancer Research , vol.57 , Issue.20 , pp. 4593-4599
- Presta, L.G.¹ Chen, H.² O'Connor, S.J.³ Chisholm, V.⁴ Meng, Y.G.⁵ Krummen, L.⁶ Winkler, M.⁷ Ferrara, N.⁸

7
- 0042343801
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
- DOI 10.1056/NEJMoa021491
- Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-34. (Pubitemid 36910021)
- (2003) New England Journal of Medicine , vol.349 , Issue.5 , pp. 427-434
- Yang, J.C.¹ Haworth, L.² Sherry, R.M.³ Hwu, P.⁴ Schwartzentruber, D.J.⁵ Topalian, S.L.⁶ Steinberg, S.M.⁷ Chen, H.X.⁸ Rosenberg, S.A.⁹

8
- 42949149159
- Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
- Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12): 2013-9.
- (2008) J Clin Oncol , vol.26 , Issue.12 , pp. 2013-2019
- Saltz, L.B.¹

9
- 34250703190
- A phase II study of temozolomide and bev-acizumab in patients with advanced neuroendocrine tumors
- Kulke MH, et al. A phase II study of temozolomide and bev-acizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006;24(18):4044.
- (2006) J Clin Oncol. , vol.24 , Issue.18 , pp. 4044
- Kulke, M.H.¹

10
- 0035447766
- Treatment with cisplatin and etoposide in patients with neuroendocrine tumors
- Fjällskog ML, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101-7.
- (2001) Cancer. , vol.92 , Issue.5 , pp. 1101-1107
- Fjällskog, M.L.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.